The increasing percentage of patients achieving deep responses in multiple myeloma (MM) has led to the need for more sophisticated instruments to measure residual disease as a potential source of relapse. Since minimal residual disease (MRD) assessment is mostly performed on a bone marrow specimen ...
The addition of daratumumab (Darzalex) to up-front triplet and quadruplet regimens in multiple myeloma has contributed to increased depth and durability of response, and although minimal residual disease (MRD) assessment has proven to be a sensitive and specific means of assessing the likelihood and...
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Keith Stewart, MBChB:Since you brought up MRD, or minimal residual disease, monitoring, let’s take a quick poll of each of you, are you using it, and at what point would you measure it first? Natalie S. Callander, MD:We’ve had a huge debate on this institutionally. We’re doing ...
Multiple Myeloma By Caroline Helwick/November 10, 2024/2024 International Myeloma Society Annual Meeting Evolving Role of MRD Status in Multiple Myeloma The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. ...
During a Case-Based Roundtable® event, Omar Nadeem, MD, and participants discussed managing toxicities of talquetamab in the second article of a 2-part series. Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma By Targeted Oncology StaffDylann Cohn-Emery De...
Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement. ORR, DOR, and Safety Outcomes with Lisaftoclax Combo Were Strong in RRMM By Dylann Cohn-Emery December 11th 2024 Overall MRD Negativity Rates Im...
000 myeloma cells in normal cells. Flow cytometry can also be used but requires special expertise. And although MRD testing is desirable, it is also problematic as a type of monitoring: It requires bone marrow testing and is technically dependent on having a good sample, Dr. Giralt ...
Improvement of transplantation strategies and a multitude of emerging novel therapies result in a better treatment outcome in patients with multiple myeloma (MM). This gives rise to the need for sensitive methods to detect minimal residual disease (MRD) in MM. Qualitative molecular monitoring using ...
EP: 7.How to Properly Utilize MRD Testing EP: 8.Varying Pertinence: MRD Testing Across Lymphomas EP: 9.Reliability of MRD Testing: Sensitivity/Specificity Now Viewing EP: 10.MRD Negativity in Multiple Myeloma EP: 11.The Value of MRD Testing in Lymphoid Malignancies Related Videos ...